We Partner for a Purpose: Our Patients
Our patients are at the heart of every decision we make. We seek out partners who share our values and commitment to improving the lives of the patients, caregivers and families we serve.
We partner with others for the advancement of research, and the development of medicines and therapeutic agents leveraging our lineage as a private company with more than 60 years of history of improving patients’ lives. We are not motivated by investors and have a sustainable business model that has led to years of success.
We are Committed to Category Leadership
Through our BioInnovation and Corporate Development teams, we actively pursue opportunities to collaborate on promising technologies that address specific unmet medical needs in our five core therapeutic areas: Oncology, Cardiology, Metabolism, Immune-inflammatory and Neuroscience. Globally, we’re committed to establishing our leadership in Oncology, intending to invest 50 percent of our R&D efforts into this therapeutic area through mergers and acquisitions, licensing deals and other collaborations.
Our leadership team focuses on how these opportunities can advance innovation in this space. We strive to serve as the ‘one-stop-shop’ for innovators looking to move quickly on R&D projects. We’re currently engaged in agreements with pharmaceutical companies (Amgen) and business accelerators (LabCentral and Plug and Play Health & Wellness), as well as academic partners, illustrated by our strategic research alliances with MIT and Harvard University.
More from Servier
We believe in driving innovation through collaboration and co-creation. By working together to discover and develop innovative cancer treatments we can help create a better world for cancer patients and their caretakers.Learn More
Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.Learn More
Research & Development
We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.Learn More
Fizkes/iStock© Getty images | vm/E+ © Getty images